Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 24 entries
Sorted by: Best Match Show Resources per page
[No title available]

Oncotarget

Pankov D, Sjöström L, Kalidindi T, Lee SG, Sjöström K, Gardner R, McDevitt MR, O'Reilly R, Thorek DLJ, Larson SM, Veach D, Ulmert D.
PMID: 29029482
Oncotarget. 2017 Jul 26;8(39):65917-65931. doi: 10.18632/oncotarget.19579. eCollection 2017 Sep 12.

Preferentially Expressed Antigen in Melanoma (PRAME) is a cancer/testis antigen that is overexpressed in a broad range of malignancies, while absent in most healthy human tissues, making it an attractive diagnostic cancer biomarker and therapeutic target. Although commonly viewed...

Cite
Pankov D, Sjöström L, Kalidindi T, et al. . Oncotarget. 2017;8(39):65917-65931doi: 10.18632/oncotarget.19579.
Pankov, D., Sjöström, L., Kalidindi, T., Lee, S. G., Sjöström, K., Gardner, R., McDevitt, M. R., O'Reilly, R., Thorek, D. L. J., Larson, S. M., Veach, D., & Ulmert, D. (2017). . Oncotarget, 8(39), 65917-65931. https://doi.org/10.18632/oncotarget.19579
Pankov, Dmitry, et al. "." Oncotarget vol. 8,39 (2017): 65917-65931. doi: https://doi.org/10.18632/oncotarget.19579
Pankov D, Sjöström L, Kalidindi T, Lee SG, Sjöström K, Gardner R, McDevitt MR, O'Reilly R, Thorek DLJ, Larson SM, Veach D, Ulmert D. . Oncotarget. 2017 Jul 26;8(39):65917-65931. doi: 10.18632/oncotarget.19579. eCollection 2017 Sep 12. PMID: 29029482; PMCID: PMC5630382.
Copy Download .nbib Format: NLM
Empiric antibiotic use in allogeneic hematopoietic cell transplantation: should we avoid anaerobe coverage?.

Blood advances

Shono Y, van den Brink MRM.
PMID: 29296882
Blood Adv. 2017 Nov 17;1(25):2325-2328. doi: 10.1182/bloodadvances.2017005108. eCollection 2017 Nov 28.

No abstract available.

Cite
Shono Y, van den Brink MRM. Empiric antibiotic use in allogeneic hematopoietic cell transplantation: should we avoid anaerobe coverage?. Blood Adv. 2017;1(25):2325-2328doi: 10.1182/bloodadvances.2017005108.
Shono, Y., & van den Brink, M. R. M. (2017). Empiric antibiotic use in allogeneic hematopoietic cell transplantation: should we avoid anaerobe coverage?. Blood advances, 1(25), 2325-2328. https://doi.org/10.1182/bloodadvances.2017005108
Shono, Yusuke, and van den Brink, Marcel R M. "Empiric antibiotic use in allogeneic hematopoietic cell transplantation: should we avoid anaerobe coverage?." Blood advances vol. 1,25 (2017): 2325-2328. doi: https://doi.org/10.1182/bloodadvances.2017005108
Shono Y, van den Brink MRM. Empiric antibiotic use in allogeneic hematopoietic cell transplantation: should we avoid anaerobe coverage?. Blood Adv. 2017 Nov 17;1(25):2325-2328. doi: 10.1182/bloodadvances.2017005108. eCollection 2017 Nov 28. PMID: 29296882; PMCID: PMC5729613.
Copy Download .nbib Format: NLM
Multifaceted Defense against Listeria monocytogenes in the Gastro-Intestinal Lumen.

Pathogens (Basel, Switzerland)

Becattini S, Pamer EG.
PMID: 29271903
Pathogens. 2017 Dec 22;7(1). doi: 10.3390/pathogens7010001.

No abstract available.

Cite
Becattini S, Pamer EG. Multifaceted Defense against Listeria monocytogenes in the Gastro-Intestinal Lumen. Pathogens. 2017;7(1)doi: 10.3390/pathogens7010001.
Becattini, S., & Pamer, E. G. (2017). Multifaceted Defense against Listeria monocytogenes in the Gastro-Intestinal Lumen. Pathogens (Basel, Switzerland), 7(1), . https://doi.org/10.3390/pathogens7010001
Becattini, Simone, and Pamer, Eric G. "Multifaceted Defense against Listeria monocytogenes in the Gastro-Intestinal Lumen." Pathogens (Basel, Switzerland) vol. 7,1 (2017). doi: https://doi.org/10.3390/pathogens7010001
Becattini S, Pamer EG. Multifaceted Defense against Listeria monocytogenes in the Gastro-Intestinal Lumen. Pathogens. 2017 Dec 22;7(1). doi: 10.3390/pathogens7010001. PMID: 29271903; PMCID: PMC5874727.
Copy Download .nbib Format: NLM
Advances in .

Advances in cell and gene therapy

Bryant AR, Perales MA.
PMID: 31106295
Adv Cell Gene Ther. 2019 Jan;2(1). doi: 10.1002/acg2.29. Epub 2018 Dec 04.

Graft-versus-host (GVHD) is an important cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). As donor T cells are recognized as key drivers of GVHD, some approaches to prevent GVHD have focused on T cell depletion of...

Cite
Bryant AR, Perales MA. Advances in . Adv Cell Gene Ther. 2018;2(1)doi: 10.1002/acg2.29.
Bryant, A. R., & Perales, M. A. (2019). Advances in . Advances in cell and gene therapy, 2(1), . https://doi.org/10.1002/acg2.29
Bryant, Adam R, and Perales, Miguel-Angel. "Advances in ." Advances in cell and gene therapy vol. 2,1 (2019). doi: https://doi.org/10.1002/acg2.29
Bryant AR, Perales MA. Advances in . Adv Cell Gene Ther. 2019 Jan;2(1). doi: 10.1002/acg2.29. Epub 2018 Dec 04. PMID: 31106295; PMCID: PMC6521977.
Copy Download .nbib Format: NLM
Utility of Bronchoscopy with Bronchoalveolar Lavage among Hematologic Transplant Recipients in the Era of Noninvasive Testing.

Respiration; international review of thoracic diseases

Feinstein MB, Habtes I, Giralt S, Stover DE.
PMID: 33626524
Respiration. 2021;100(4):339-346. doi: 10.1159/000512376. Epub 2021 Feb 24.

BACKGROUND: Pulmonary complications are common among hematologic stem cell transplant (HSCT) recipients. Their evaluation can be pursued through bronchoscopy with bronchoalveolar lavage (BAL) and a variety of available noninvasive studies, which include newer molecular markers for detecting a variety...

Cite
Feinstein MB, Habtes I, Giralt S, et al. Utility of Bronchoscopy with Bronchoalveolar Lavage among Hematologic Transplant Recipients in the Era of Noninvasive Testing. Respiration. 2021;100(4):339-346doi: 10.1159/000512376.
Feinstein, M. B., Habtes, I., Giralt, S., & Stover, D. E. (2021). Utility of Bronchoscopy with Bronchoalveolar Lavage among Hematologic Transplant Recipients in the Era of Noninvasive Testing. Respiration; international review of thoracic diseases, 100(4), 339-346. https://doi.org/10.1159/000512376
Feinstein, Marc B, et al. "Utility of Bronchoscopy with Bronchoalveolar Lavage among Hematologic Transplant Recipients in the Era of Noninvasive Testing." Respiration; international review of thoracic diseases vol. 100,4 (2021): 339-346. doi: https://doi.org/10.1159/000512376
Feinstein MB, Habtes I, Giralt S, Stover DE. Utility of Bronchoscopy with Bronchoalveolar Lavage among Hematologic Transplant Recipients in the Era of Noninvasive Testing. Respiration. 2021;100(4):339-346. doi: 10.1159/000512376. Epub 2021 Feb 24. PMID: 33626524; PMCID: PMC8035270.
Copy Download .nbib Format: NLM
Establishing a standardized system for review and adjudication of chronic graft-vs-host disease data in accordance with the National Institutes Consensus criteria.

Advances in cell and gene therapy

Dierov D, Webb N, Fatmi S, Nwanne C, Ciolino C, Mosesso K, Nieves J, Perales MA, Prockop SE, Ponce DM.
PMID: 31886456
Adv Cell Gene Ther. 2019 Oct;2(4). doi: 10.1002/acg2.62. Epub 2019 May 02.

GVHD is a frequent complication following allo-HCT. The NIH consensus group established new guidelines for the evaluation of chronic GVHD. However, GVHD assessment remains challenging due its complexity and requirement for laborious evaluation. We, therefore, established a standardized approach...

Cite
Dierov D, Webb N, Fatmi S, et al. Establishing a standardized system for review and adjudication of chronic graft-vs-host disease data in accordance with the National Institutes Consensus criteria. Adv Cell Gene Ther. 2019;2(4)doi: 10.1002/acg2.62.
Dierov, D., Webb, N., Fatmi, S., Nwanne, C., Ciolino, C., Mosesso, K., Nieves, J., Perales, M. A., Prockop, S. E., & Ponce, D. M. (2019). Establishing a standardized system for review and adjudication of chronic graft-vs-host disease data in accordance with the National Institutes Consensus criteria. Advances in cell and gene therapy, 2(4), . https://doi.org/10.1002/acg2.62
Dierov, Djamilia, et al. "Establishing a standardized system for review and adjudication of chronic graft-vs-host disease data in accordance with the National Institutes Consensus criteria." Advances in cell and gene therapy vol. 2,4 (2019). doi: https://doi.org/10.1002/acg2.62
Dierov D, Webb N, Fatmi S, Nwanne C, Ciolino C, Mosesso K, Nieves J, Perales MA, Prockop SE, Ponce DM. Establishing a standardized system for review and adjudication of chronic graft-vs-host disease data in accordance with the National Institutes Consensus criteria. Adv Cell Gene Ther. 2019 Oct;2(4). doi: 10.1002/acg2.62. Epub 2019 May 02. PMID: 31886456; PMCID: PMC6934358.
Copy Download .nbib Format: NLM
Hematopoietic Cell Transplantation is Feasible in Patients with Prior COVID-19 Infection.

Transplantation and cellular therapy

Shah N, Dahi PB, Ponce DM, Sauter CS, Shaffer BC, Chung DJ, Politikos I, Lin RJ, Giralt SA, Papanicolaou G, Ramanathan LV, Perales MA, Kamboj M, Shah GL, Gyurkocza B.
PMID: 34649021
Transplant Cell Ther. 2021 Oct 11; doi: 10.1016/j.jtct.2021.10.004. Epub 2021 Oct 11.

There are limited data on outcomes of patients with prior Coronavirus disease 2019 (COVID-19) who proceeded to autologous or allogeneic hematopoietic cell transplantation (HCT). Whether these patients are more susceptible to poor outcomes and recurrence of COVID-19 is unknown....

Cite
Shah N, Dahi PB, Ponce DM, et al. Hematopoietic Cell Transplantation is Feasible in Patients with Prior COVID-19 Infection. Transplant Cell Ther. 2021;doi: 10.1016/j.jtct.2021.10.004.
Shah, N., Dahi, P. B., Ponce, D. M., Sauter, C. S., Shaffer, B. C., Chung, D. J., Politikos, I., Lin, R. J., Giralt, S. A., Papanicolaou, G., Ramanathan, L. V., Perales, M. A., Kamboj, M., Shah, G. L., & Gyurkocza, B. (2021). Hematopoietic Cell Transplantation is Feasible in Patients with Prior COVID-19 Infection. Transplantation and cellular therapy, . https://doi.org/10.1016/j.jtct.2021.10.004
Shah, Nishi, et al. "Hematopoietic Cell Transplantation is Feasible in Patients with Prior COVID-19 Infection." Transplantation and cellular therapy vol. (2021). doi: https://doi.org/10.1016/j.jtct.2021.10.004
Shah N, Dahi PB, Ponce DM, Sauter CS, Shaffer BC, Chung DJ, Politikos I, Lin RJ, Giralt SA, Papanicolaou G, Ramanathan LV, Perales MA, Kamboj M, Shah GL, Gyurkocza B. Hematopoietic Cell Transplantation is Feasible in Patients with Prior COVID-19 Infection. Transplant Cell Ther. 2021 Oct 11; doi: 10.1016/j.jtct.2021.10.004. Epub 2021 Oct 11. PMID: 34649021; PMCID: PMC8503970.
Copy Download .nbib Format: NLM
Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies.

Blood cancer discovery

Chung DJ, Shah GL, Devlin SM, Ramanathan LV, Doddi S, Pessin MS, Hoover E, Marcello LT, Young JC, Boutemine SR, Serrano E, Sharan S, Momotaj S, Margetich L, Bravo CD, Papanicolaou GA, Kamboj M, Mato AR, Roeker LE, Hultcrantz M, Mailankody S, Lesokhin AM, Vardhana SA, Knorr DA.
PMID: 34778797
Blood Cancer Discov. 2021 Sep 13;2(6):568-576. doi: 10.1158/2643-3230.BCD-21-0139. eCollection 2021 Nov.

Coronavirus disease-19 (COVID-19) vaccine response data for patients with hematologic malignancy, who carry high risk for severe COVID-19 illness, are incomplete. In a study of 551 hematologic malignancy patients with leukemia, lymphoma, and multiple myeloma, anti-SARS-CoV-2 spike IgG titers...

Cite
Chung DJ, Shah GL, Devlin SM, et al. Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies. Blood Cancer Discov. 2021;2(6):568-576doi: 10.1158/2643-3230.BCD-21-0139.
Chung, D. J., Shah, G. L., Devlin, S. M., Ramanathan, L. V., Doddi, S., Pessin, M. S., Hoover, E., Marcello, L. T., Young, J. C., Boutemine, S. R., Serrano, E., Sharan, S., Momotaj, S., Margetich, L., Bravo, C. D., Papanicolaou, G. A., Kamboj, M., Mato, A. R., Roeker, L. E., Hultcrantz, M., Mailankody, S., Lesokhin, A. M., Vardhana, S. A., & Knorr, D. A. (2021). Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies. Blood cancer discovery, 2(6), 568-576. https://doi.org/10.1158/2643-3230.BCD-21-0139
Chung, David J, et al. "Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies." Blood cancer discovery vol. 2,6 (2021): 568-576. doi: https://doi.org/10.1158/2643-3230.BCD-21-0139
Chung DJ, Shah GL, Devlin SM, Ramanathan LV, Doddi S, Pessin MS, Hoover E, Marcello LT, Young JC, Boutemine SR, Serrano E, Sharan S, Momotaj S, Margetich L, Bravo CD, Papanicolaou GA, Kamboj M, Mato AR, Roeker LE, Hultcrantz M, Mailankody S, Lesokhin AM, Vardhana SA, Knorr DA. Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies. Blood Cancer Discov. 2021 Sep 13;2(6):568-576. doi: 10.1158/2643-3230.BCD-21-0139. eCollection 2021 Nov. PMID: 34778797; PMCID: PMC8580617.
Copy Download .nbib Format: NLM
Dynamic variability in SHP-1 abundance determines natural killer cell responsiveness.

Science signaling

Wu Z, Park S, Lau CM, Zhong Y, Sheppard S, Sun JC, Das J, Altan-Bonnet G, Hsu KC.
PMID: 34752140
Sci Signal. 2021 Nov 09;14(708):eabe5380. doi: 10.1126/scisignal.abe5380. Epub 2021 Nov 09.

[Figure: see text].

Cite
Wu Z, Park S, Lau CM, et al. Dynamic variability in SHP-1 abundance determines natural killer cell responsiveness. Sci Signal. 2021;14(708):eabe5380doi: 10.1126/scisignal.abe5380.
Wu, Z., Park, S., Lau, C. M., Zhong, Y., Sheppard, S., Sun, J. C., Das, J., Altan-Bonnet, G., & Hsu, K. C. (2021). Dynamic variability in SHP-1 abundance determines natural killer cell responsiveness. Science signaling, 14(708), eabe5380. https://doi.org/10.1126/scisignal.abe5380
Wu, Zeguang, et al. "Dynamic variability in SHP-1 abundance determines natural killer cell responsiveness." Science signaling vol. 14,708 (2021): eabe5380. doi: https://doi.org/10.1126/scisignal.abe5380
Wu Z, Park S, Lau CM, Zhong Y, Sheppard S, Sun JC, Das J, Altan-Bonnet G, Hsu KC. Dynamic variability in SHP-1 abundance determines natural killer cell responsiveness. Sci Signal. 2021 Nov 09;14(708):eabe5380. doi: 10.1126/scisignal.abe5380. Epub 2021 Nov 09. PMID: 34752140.
Copy Download .nbib Format: NLM
Effects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML Patients.

Journal of clinical medicine

Hobbs GS, Perales MA.
PMID: 26239251
J Clin Med. 2015 Mar 19;4(3):488-503. doi: 10.3390/jcm4030488.

Graft versus host disease (GVHD) remains one of the leading causes of morbidity and mortality associated with conventional allogeneic hematopoietic stem cell transplantation (HCT). The use of T-cell depletion significantly reduces this complication. Recent prospective and retrospective data suggest...

Cite
Hobbs GS, Perales MA. Effects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML Patients. J Clin Med. 2015;4(3):488-503doi: 10.3390/jcm4030488.
Hobbs, G. S., & Perales, M. A. (2015). Effects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML Patients. Journal of clinical medicine, 4(3), 488-503. https://doi.org/10.3390/jcm4030488
Hobbs, Gabriela Soriano, and Perales, Miguel-Angel. "Effects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML Patients." Journal of clinical medicine vol. 4,3 (2015): 488-503. doi: https://doi.org/10.3390/jcm4030488
Hobbs GS, Perales MA. Effects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML Patients. J Clin Med. 2015 Mar 19;4(3):488-503. doi: 10.3390/jcm4030488. PMID: 26239251; PMCID: PMC4470141.
Copy Download .nbib Format: NLM
Allogeneic hematopoietic cell transplantation for older patients.

Hematology. American Society of Hematology. Education Program

Lin RJ, Artz AS.
PMID: 34889392
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):254-263. doi: 10.1182/hematology.2021000257.

Hematologic malignances are more common and often higher risk in older patients. Allogeneic hematopoietic cell transplantation (alloHCT) best enables long-term disease control for patients with poor risk or relapsed/refractory hematologic malignancies such as acute myeloid leukemia, myelodysplastic syndromes, or...

Cite
Lin RJ, Artz AS. Allogeneic hematopoietic cell transplantation for older patients. Hematology Am Soc Hematol Educ Program. 2021;2021(1):254-263doi: 10.1182/hematology.2021000257.
Lin, R. J., & Artz, A. S. (2021). Allogeneic hematopoietic cell transplantation for older patients. Hematology. American Society of Hematology. Education Program, 2021(1), 254-263. https://doi.org/10.1182/hematology.2021000257
Lin, Richard J, and Artz, Andrew S. "Allogeneic hematopoietic cell transplantation for older patients." Hematology. American Society of Hematology. Education Program vol. 2021,1 (2021): 254-263. doi: https://doi.org/10.1182/hematology.2021000257
Lin RJ, Artz AS. Allogeneic hematopoietic cell transplantation for older patients. Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):254-263. doi: 10.1182/hematology.2021000257. PMID: 34889392.
Copy Download .nbib Format: NLM
Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy.

Blood cancer discovery

Tamari R, Politikos I, Knorr DA, Vardhana SA, Young JC, Marcello LT, Doddi S, Devlin SM, Ramanathan LV, Pessin MS, Dunn E, Palazzo M, Bravo CD, Papanicolaou GA, Kamboj M, Perales MA, Chung DJ, Shah GL.
PMID: 34778798
Blood Cancer Discov. 2021 Sep 13;2(6):577-585. doi: 10.1158/2643-3230.BCD-21-0142. eCollection 2021 Nov.

Cellular therapies including allogeneic hematopoietic cell transplant (allo-HCT) and autologous hematopoietic cell transplant (auto-HCT) and chimeric antigen receptor (CAR) T-cell therapy render patients severely immunocompromised for extended periods after therapy, and data on responses to COVID-19 vaccines are limited....

Cite
Tamari R, Politikos I, Knorr DA, et al. Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy. Blood Cancer Discov. 2021;2(6):577-585doi: 10.1158/2643-3230.BCD-21-0142.
Tamari, R., Politikos, I., Knorr, D. A., Vardhana, S. A., Young, J. C., Marcello, L. T., Doddi, S., Devlin, S. M., Ramanathan, L. V., Pessin, M. S., Dunn, E., Palazzo, M., Bravo, C. D., Papanicolaou, G. A., Kamboj, M., Perales, M. A., Chung, D. J., & Shah, G. L. (2021). Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy. Blood cancer discovery, 2(6), 577-585. https://doi.org/10.1158/2643-3230.BCD-21-0142
Tamari, Roni, et al. "Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy." Blood cancer discovery vol. 2,6 (2021): 577-585. doi: https://doi.org/10.1158/2643-3230.BCD-21-0142
Tamari R, Politikos I, Knorr DA, Vardhana SA, Young JC, Marcello LT, Doddi S, Devlin SM, Ramanathan LV, Pessin MS, Dunn E, Palazzo M, Bravo CD, Papanicolaou GA, Kamboj M, Perales MA, Chung DJ, Shah GL. Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy. Blood Cancer Discov. 2021 Sep 13;2(6):577-585. doi: 10.1158/2643-3230.BCD-21-0142. eCollection 2021 Nov. PMID: 34778798; PMCID: PMC8580614.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 24 entries